Search

Your search keyword '"Naume B."' showing total 304 results

Search Constraints

Start Over You searched for: Author "Naume B." Remove constraint Author: "Naume B."
304 results on '"Naume B."'

Search Results

1. Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer—a prospective national multicentre study (EMIT-1)

4. 103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1)

5. Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

6. 215MO ICON – a randomized phase IIb study evaluating chemotherapy combined with ipilimumab and nivolumab in metastatic hormone receptor-positive breast cancer

8. 182P Radium-223 (223Ra) in combination with exemestane and everolimus (EXE-EVE) in patients (pts) with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) with bone metastases: A phase II study

9. DNA copy number motifs are strong and independent predictors of survival in breast cancer

11. Mendelian randomisation study of smoking exposure in relation to breast cancer risk

12. Mendelian randomisation study of smoking exposure in relation to breast cancer risk.

13. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers.

15. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

16. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk.

19. Two truncating variants in FANCC and breast cancer risk

20. International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer : Results from the PADDY study

22. Two truncating variants in FANCC and breast cancer risk

23. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

24. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes

28. Abstract GS5-07: International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study

29. Abstract P6-07-01: A translational and five-year clinical update in patients treated with neoadjuvant chemotherapy randomized to bevacizumab or control in HER2 negative breast cancer

30. Abstract OT1-05-02: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high clinical risk early breast cancer

31. Comparison of the Agilent, ROMA/NimbleGen and Illumina platforms for classification of copy number alterations in human breast tumors

33. Abstract P3-12-05: Serum levels of the active tamoxifen metabolite Z-4OHtam is predictive of long-term survival in luminal B subtype of breast cancer patients

34. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients

35. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients

36. Safety of Everolimus Plus Exemestane In Patients With Hormone-Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Progressing on Prior Non-Steroidal Aromatase Inhibitors: Primary Results of a Phase 3b, Open-Label, Single-Arm, Expanded-Access Multicenter Trial (BALLET)

39. Abstract P6-13-01: Proteomic response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Reverse phase protein array (RPPA) results from NeoAva - A randomized phase II study

40. Abstract S3-01: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy

41. Abstract P2-05-16: Establishment of molecular profiling for individual treatment decisions in early breast cancer – Clinical impact of PAM50 and PAM50 risk of recurrence score after more than 16 years follow up

43. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling

44. Allele-specific copy number analysis of tumors

45. Long non-coding RNAs differentially expressed between normal versus primary breast tumor tissues disclose converse changes to breast cancer-related protein-coding genes

46. International study on inter-reader variability for circulating tumor cells in breast cancer

49. Abstract P4-14-02: Molecular response in breast cancer tumors treated with neoadjuvant chemotherapy with and without bevacizumab: Results from NeoAva - A randomized phase II study

50. Abstract P4-14-01: A time course study of genomic instability in breast cancer patients receiving neoadjuvant therapy with or without bevacizumab

Catalog

Books, media, physical & digital resources